Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954295544> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2954295544 endingPage "S99" @default.
- W2954295544 startingPage "S98" @default.
- W2954295544 abstract "European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) have developed frameworks for clinical benefit assessment of cancer treatments. The concordance in scoring using these frameworks has been studied in Cherny 2018. Value of a therapy from a payer’s perspective additionally includes economic and financial considerations. This study examines the concordance of UK’s National Institute for Clinical Excellence (NICE) decisions with ASCO and ESMO’s clinical benefit assessment. Scoring on ASCO and ESMO frameworks for 102 advanced oncology drugs were taken from Cherny 2018. Corresponding final appraisal documents by NICE were reviewed. Data were extracted for indication, comparators, clinical benefit assessment, toxicity, quality of life, and cost-effectiveness. NICE committee’s final decision was recorded: recommended or not, with restriction in indication or with a patient access scheme (PAS) or on the cancer drugs fund (CDF). The relationship between ASCO/ESMO scores and NICE recommendation was investigated. 79% of the 102 drugs included in Cherny 2018 were assessed by NICE; 45% were recommended by NICE, 22% were with PAS and 12% on the CDF. Of the recommended treatments, 82% and 93% were associated with a moderate to high clinical benefit score on ASCO (>40) and ESMO (>3), respectively. Treatments with restricted recommendation based on indication and on CDF were associated with the highest mean ASCO (54) and ESMO (4) benefit score. Cost-effectiveness was less correlated with clinical scoring, potentially suggesting that pricing does not fully reflect clinical benefit. The cost-effectiveness analysis was limited by the confidential nature of the final agreed price. An association was found between NICE recommendations and clinical benefit assessments by ASCO and ESMO despite the difference in performance criteria, clinical evidence, comparator choice, disease burden, and cost-effectiveness, adopted by payers and clinical frameworks." @default.
- W2954295544 created "2019-07-12" @default.
- W2954295544 creator A5000218289 @default.
- W2954295544 creator A5016695775 @default.
- W2954295544 creator A5023564727 @default.
- W2954295544 creator A5056195662 @default.
- W2954295544 creator A5090002594 @default.
- W2954295544 date "2019-05-01" @default.
- W2954295544 modified "2023-09-30" @default.
- W2954295544 title "PCN225 VALUE FOR PAYERS VS. PHYSICIANS: IS THERE CONVERGENCE BETWEEN VALUE ASSESSMENT BY ESMO, ASCO AND UK NICE DECISION?" @default.
- W2954295544 doi "https://doi.org/10.1016/j.jval.2019.04.347" @default.
- W2954295544 hasPublicationYear "2019" @default.
- W2954295544 type Work @default.
- W2954295544 sameAs 2954295544 @default.
- W2954295544 citedByCount "0" @default.
- W2954295544 crossrefType "journal-article" @default.
- W2954295544 hasAuthorship W2954295544A5000218289 @default.
- W2954295544 hasAuthorship W2954295544A5016695775 @default.
- W2954295544 hasAuthorship W2954295544A5023564727 @default.
- W2954295544 hasAuthorship W2954295544A5056195662 @default.
- W2954295544 hasAuthorship W2954295544A5090002594 @default.
- W2954295544 hasBestOaLocation W29542955441 @default.
- W2954295544 hasConcept C112930515 @default.
- W2954295544 hasConcept C126322002 @default.
- W2954295544 hasConcept C144133560 @default.
- W2954295544 hasConcept C160798450 @default.
- W2954295544 hasConcept C162118730 @default.
- W2954295544 hasConcept C17744445 @default.
- W2954295544 hasConcept C199360897 @default.
- W2954295544 hasConcept C199539241 @default.
- W2954295544 hasConcept C2777352838 @default.
- W2954295544 hasConcept C2779256446 @default.
- W2954295544 hasConcept C3019080777 @default.
- W2954295544 hasConcept C41008148 @default.
- W2954295544 hasConcept C512399662 @default.
- W2954295544 hasConcept C71924100 @default.
- W2954295544 hasConceptScore W2954295544C112930515 @default.
- W2954295544 hasConceptScore W2954295544C126322002 @default.
- W2954295544 hasConceptScore W2954295544C144133560 @default.
- W2954295544 hasConceptScore W2954295544C160798450 @default.
- W2954295544 hasConceptScore W2954295544C162118730 @default.
- W2954295544 hasConceptScore W2954295544C17744445 @default.
- W2954295544 hasConceptScore W2954295544C199360897 @default.
- W2954295544 hasConceptScore W2954295544C199539241 @default.
- W2954295544 hasConceptScore W2954295544C2777352838 @default.
- W2954295544 hasConceptScore W2954295544C2779256446 @default.
- W2954295544 hasConceptScore W2954295544C3019080777 @default.
- W2954295544 hasConceptScore W2954295544C41008148 @default.
- W2954295544 hasConceptScore W2954295544C512399662 @default.
- W2954295544 hasConceptScore W2954295544C71924100 @default.
- W2954295544 hasLocation W29542955441 @default.
- W2954295544 hasOpenAccess W2954295544 @default.
- W2954295544 hasPrimaryLocation W29542955441 @default.
- W2954295544 hasRelatedWork W1935811877 @default.
- W2954295544 hasRelatedWork W2013151644 @default.
- W2954295544 hasRelatedWork W2025373866 @default.
- W2954295544 hasRelatedWork W2073681061 @default.
- W2954295544 hasRelatedWork W2129750793 @default.
- W2954295544 hasRelatedWork W2225428663 @default.
- W2954295544 hasRelatedWork W2544355323 @default.
- W2954295544 hasRelatedWork W3122491543 @default.
- W2954295544 hasRelatedWork W4311339323 @default.
- W2954295544 hasRelatedWork W48400510 @default.
- W2954295544 hasVolume "22" @default.
- W2954295544 isParatext "false" @default.
- W2954295544 isRetracted "false" @default.
- W2954295544 magId "2954295544" @default.
- W2954295544 workType "article" @default.